Naifa Busaidy


Affiliation: The University of Texas
Country: USA


  1. Iyer P, Cabanillas M, Waguespack S, Hu M, Thosani S, Lavis V, et al. Immune Checkpoint Inhibitor mediated Thyroiditis. Thyroid. 2018;: pubmed publisher
    ..The evolution of irT is more rapid with combination ICI. Frequent monitoring of TFTs during ICI is warranted. Future guidelines need to recognize this entity and incorporate their management. ..
  2. Tam S, Boonsripitayanon M, Amit M, Fellman B, Li Y, Busaidy N, et al. Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging 7th and 8th editions. Thyroid. 2018;: pubmed publisher
    ..Potential modifications that may improve disease-specific survival prediction in future renditions include reconsideration of T3b tumor category and upstaging classification of patients < 55 years of age with distant metastases. ..
  3. Busaidy N, Farooki A, Dowlati A, Perentesis J, Dancey J, DOYLE L, et al. Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol. 2012;30:2919-28 pubmed publisher
    ..Specialty consultation should be sought to aid clinical trial planning and the management of these metabolic adverse events. ..
  4. Cabanillas M, Ferrarotto R, Garden A, Ahmed S, Busaidy N, Dadu R, et al. Neoadjuvant BRAF- and immune- directed therapy for anaplastic thyroid carcinoma. Thyroid. 2018;: pubmed publisher
    ..This novel neoadjuvant approach to BRAF-mutated ATC should be studied in further in clinical trials. ..
  5. Tam S, Amit M, Boonsripitayanon M, Busaidy N, Cabanillas M, Waguespack S, et al. The Effect of Tumor Size and Minimal Extrathyroidal Extension in Patients with Differentiated Thyroid Cancer. Thyroid. 2018;: pubmed publisher
    ..Group 3 [>4cm with mETE] HRadjusted=1.0, 95% CI=0.5-2.3). For LRF and DMF, size but not mETE was also an independent risk factor. Tumor size, and not the presence of mETE, was an independent predictor of DFS, LRF, and DMF in DTC. ..
  6. Silva Figueroa A, Hess K, Williams M, Clarke C, Christakis I, Graham P, et al. Prognostic Scoring System to Risk Stratify Parathyroid Carcinoma. J Am Coll Surg. 2017;: pubmed publisher
    ..This categorization might be helpful for clinical decisions relative to the timing and use of adjuvant therapy. Comprehensive validation using multiple cohorts will be needed to confirm applicability. ..
  7. Iyer P, Dadu R, Ferrarotto R, Busaidy N, Habra M, Zafereo M, et al. Real world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma. Thyroid. 2017;: pubmed publisher
    ..Patients with anaplastic thyroid cancer (ATC) have a dismal prognosis despite systemic cytotoxic chemotherapy. Our objective was to study the efficacy and safety of targeted therapy in ATC patients when used outside of a clinical trial...